CEPHRADINE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=69176
Curator's Comment:: https://www.drugs.com/mtm/cephradine.html | http://www.medicinenet.com/cephradine-oral/article.htm | https://www.ncbi.nlm.nih.gov/pubmed/4684646

Cephradine is a semisynthetic cephalosporin antibiotic. Cephradine is active against the following organisms in vitro: Group A beta-hemolytic streptococci; Staphylococci, including coagulase-positive, coagulase-negative, and penicillinase-producing strains; Streptococcus pneumoniae (formerly Diplococcus pneumoniae); Escherichia coli; Proteus mirabilis; Klebsiella species; Hemophilus influenza. It works by stopping the growth of bacteria. It is used to treat a wide variety of bacterial infections (e.g., skin, ear, respiratory and urinary tract infections). Pseudomembranous colitis has been reported in patients receiving cephradine both orally and intravenously. Diarrhea generally starts 1 to 16 days after starting cephradine therapy. Gastrointestinal side effects have included nausea, vomiting. Hypersensitivity reactions have included rash, urticaria, pruritus, and joint pain. Bacteriostats may interfere with the bactericidal action of cephalosporins in acute infection; other agents, e.g., aminoglycosides, colistin, polymyxins, vancomycin, may increase the possibility of nephrotoxicity.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 226 Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19015345 \| https://www.ncbi.nlm.nih.gov/pubmed/7592463 \| https://www.ncbi.nlm.nih.gov/pubmed/6373702	Inhibitor 7701	Respiratory tract infections Otitis media Skin and skin structure infections Urinary tract infections	30 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Respiratory tract infections 84 Sources: https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=69176	Curative	Bacterial penicillin-binding protein	Approved 7997	VELOSEF '125' Approved Use Cephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date 146102400000
Otitis media 39 Sources: https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=69176	Curative	Bacterial penicillin-binding protein	Approved 7997	VELOSEF '125' Approved Use Cephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date 146102400000
Skin and skin structure infections 77 Sources: https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=69176	Curative	Bacterial penicillin-binding protein	Approved 7997	VELOSEF '125' Approved Use Cephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date 146102400000
Urinary tract infections 197 Sources: https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=69176	Curative	Bacterial penicillin-binding protein	Approved 7997	VELOSEF '125' Approved Use Cephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date 146102400000

C_max

Value	Dose	Co-administered	Analyte	Population
17.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		CEPHRADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
27.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		CEPHRADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.61 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		CEPHRADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00ILYH
A2B Chem	AI67465
AA Blocks	AA00ILF1
AK Scientific	6526AH
AK Scientific	6527AH
AK Scientific	E914
AbovChem LLC	HY-B1156
Ambeed	A114890
Angene	AGN-PC-0RHN84
AstaTech	C74975
BLDpharm	BD46333
BOC Sciences	38821-53-3
Bosche Scientific	C2321
Chem Scene	CS-4608
Chem-Impex International	14312
Compound Cloud	38103
Enamine	EN300-6479201
Fluorochem	493329
Hangzhou APIChem Technology	AC-1409
Hangzhou Yuhao Chemical Technology	RT19741
KeyOrganics	AS-75158
Lab Network	LN01268780
Lab Seeker	SC-13473
MedChem Express	HY-B1156
MolPort	MolPort-003-940-846
MolPort	MolPort-039-140-513
Norris Pharm	NSZB-A200423
Ryan Scientific	Sodium_ceftiofur
Sigma Aldrich	BP063
Sigma Aldrich	C0690000
Sigma Aldrich	C0690000\|SIAL
Sigma Aldrich	C8395
Sigma Aldrich	C8395\|SIGMA
Sigma Aldrich	Y0000568
Sigma Aldrich	Y0000568\|SIAL
StruChem	SC-13473
TargetMol	T0199
Tetrahedron	TS64686
Toronto Research Chemicals	C261800
W&J PharmaChem	100988
ZINC	ZINC000003830515	http://zinc15.docking.org/substances/ZINC000003830515
eMolecules	536524
mcule	MCULE-5616371730

PubMed

Title	Date	PubMed
Capillary electrophoresis study on the micellization and critical micelle concentration of sodium dodecyl sulfate. Influence of solubilized solutes.	2001 Jul 27	11521911
Effect of UV-B radiation on some common antibiotics.	2002 Apr	11869874
Clinical significance and epidemiology of NO-1, an unusual bacterium associated with dog and cat bites.	2002 Feb	11897069
Transport and utilization of arginine and arginine-containing peptides by rat alveolar macrophages.	2002 Jun	12134953
Prolonged intestinal absorption of cephradine with chitosan-coated ethylcellulose microparticles in rats.	2002 Nov	12419970
A recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference.	2003 Apr	12942684
Sensitive determination of a beta-lactam antibiotic, cefaclor by liquid chromatography with chemiluminescence detection.	2003 Jan 15	12485718
Symphyseal diastasis and vestibular rupture during spontaneous vaginal delivery.	2003 Jun	12798485
Treatment of breast abscesses with sonographically guided aspiration, irrigation, and instillation of antibiotics.	2003 Oct	14500237
Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: An eradication protocol.	2003 Sep	12910579
Microbiology and drug sensitivity patterns of chronic suppurative otitis media.	2004 Aug	15321034
Preparation and characterization of porous hollow silica nanoparticles for drug delivery application.	2004 Feb	14607511
Re: "Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol" Solis et al. (Pediatr Pulmonol 2003;36: 189-195).	2004 Sep	15274111
Purification and characterization of inducible cephalexin synthesizing enzyme in Gluconobacter oxydans.	2005 Mar	15784972
Systemic and local antibiotic prophylaxis in the prevention of Staphylococcus epidermidis graft infection.	2005 Oct 21	16242027
Properties and active substance release kinetics from gelatin-alginate matrices.	2006	17190292
Crystal form of cephradine.	2006 Feb	16526284
Controlled drug delivery system based on magnetic hollow spheres/polyelectrolyte multilayer core-shell structure.	2006 Sep-Oct	17048538
Characterization of beta-lactamases from urinary isolates of Escherichia coli in Tehran.	2007 Apr	18051951
Determination of beta-lactam antibiotics in milk using micro-flow chemiluminescence system with on-line solid phase extraction.	2007 Jun 5	17512825
Use of SDS micelles for improving sensitivity, resolution, and speed in the analysis of beta-lactam antibiotics in environmental waters by SPE and CE.	2007 Sep	17854115
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine.	2008 Aug	18505790
Effects of treatment with antimicrobial agents on the human colonic microflora.	2008 Dec	19337440
Human case of Rickettsia felis infection, Taiwan.	2008 Dec	19046543
Characteristics of Streptococcus pyogenes strains isolated from Chinese children with scarlet fever.	2008 Dec	18691162
[Prophylactic use of antibiotics in selective colorectal operation: a randomized controlled trial].	2008 Jan 15	18509971
Pharmacokinetic study of cephradine in Pakistani healthy male volunteers.	2008 Oct	18930862
Studies on diseased freshwater prawn Macrobrachium rosenbergii infected with Vibrio vulnificus.	2008 Sep 1	19266922
Kinetic spectrophotometric determination of certain cephalosporins in pharmaceutical formulations.	2009	20140078
Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes.	2009	19209224
A study of the chemiluminescence behavior of cephalosporins with luminol and its analytical application.	2009 Aug	19702549
[Analysis of multiple cephalosporins in blood and urine by HPLC].	2009 Dec	20225621
Rapid and simple method for determination of cephradine in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS): application to the bioequivalence study.	2009 Dec 1	19854118
Antibiotics for mastitis in breastfeeding women.	2009 Jan 21	19160255
Lack of interaction between the peptidomimetic substrates captopril and cephradine.	2009 Mar	19246733
Traumatic optic neuropathy accompanying orbital grease gun injury.	2010 Apr	20379466
Colorimetric detection of cephradine in pharmaceutical formulations via fluorosurfactant-capped gold nanoparticles.	2010 Apr 15	20188984
Avian colibacillosis and salmonellosis: a closer look at epidemiology, pathogenesis, diagnosis, control and public health concerns.	2010 Jan	20195435
Selective densitometric determination of four alpha-aminocephalosporins using ninhydrin reagent.	2010 Jan	20056040
Uropathogen resistance to antibiotic prophylaxis in urinary tract infections.	2010 Jun	20370510
Rate of conversion and complications of laparoscopic cholecystectomy in a tertiary care center in Saudi Arabia.	2010 Mar-Apr	20220265

Patents

Sample Use Guides

In Vivo Use Guide

For respiratory tract infections (other than lobar pneumonia) and skin and skin structure infections, the usual dose is 250 mg every 6 hours or 500 mg every 12 hours.

Route of Administration: Oral

In Vitro Use Guide

MIC 90 of Cephradine standard powder against 25 clinical isolates of S. aureus was 2048 ug/ml.

Substance Class	Mixture Created by `admin` on `Fri Jun 25 20:52:02 UTC 2021` Edited by `admin` on `Fri Jun 25 20:52:02 UTC 2021`
Record UNII	F1BC02I72W
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CEPHRADINE

Official Name

English

VELOSEF

Brand Name

English

CEPHRADINE HYDRATE [MART.]

Common Name

English

CEPHRADINE [USP-RS]

Common Name

English

CEFRADINE HYDRATE

Common Name

English

CEPHRADINE [VANDF]

Common Name

English

SK&F-D-39304

Code

English

SQ-11436

Code

English

SQ-22022

Code

English

CEPHRADINE [USP MONOGRAPH]

Common Name

English

ANSPOR

Brand Name

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(2-AMINO-2-(1,4-CYCLOHEXADIEN-1-YL)ACETAMIDO)-3-METHYL-8-OXO-, HYDRATE, D-

Common Name

English

CEPHRADINE NON-STOICHIOMETRIC HYDRATE FORM

Common Name

English

SQ 11436

Code

English

CEPHRADINE, UNSPECIFIED HYDRATE

Common Name

English

CEPHRADINE [ORANGE BOOK]

Common Name

English

CEPHRADINE [USAN]

Common Name

English

CEPHRADINE HYDRATE

Common Name

English

SK&F D-39304

Code

English

Classification Tree Code System Code

WHO-ATC

J01DB09